TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia

Ibrutinib may revert the T-helper (Th)2 polarization observed in chronic lymphocytic leukemia (CLL) by targeting the IL-2-inducible kinase, that shows a significant homology with the Bruton tyrosine kinase. In the front-line GIMEMA LLC1114 trial (ibrutinib+rituximab for 6 months, followed by ibrutin...

Full description

Bibliographic Details
Main Authors: Maria Cristina Puzzolo, Ilaria Del Giudice, Nadia Peragine, Paola Mariglia, Maria Stefania De Propris, Luca Vincenzo Cappelli, Livio Trentin, Gianluigi Reda, Antonio Cuneo, Stefano Molica, Alfonso Piciocchi, Valentina Arena, Francesca Romana Mauro, Anna Guarini, Robin Foà
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
chronic lymphocytic leukemia
ibrutinib
Th1
Th2
T lymphocytes
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.637186/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.637186/full

Similar Items